Clinical Trials Logo

Recurrent Intraocular Melanoma clinical trials

View clinical trials related to Recurrent Intraocular Melanoma.

Filter by:

NCT ID: NCT01730157 Terminated - Liver Metastases Clinical Trials

Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases

Start date: December 2012
Phase: Phase 0
Study type: Interventional

This pilot clinical trial studies radioembolization and ipilimumab in treating patients with uveal melanoma with liver metastases. Radioembolization kills tumor cells by blocking the blood flow to the tumor and keeping radioactive substances near the tumor. Monoclonal antibodies, such as ipilimumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving radioembolization together with ipilimumab may kill more tumor cells in patients with uveal melanoma

NCT ID: NCT01533948 Terminated - Recurrent Melanoma Clinical Trials

Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery

Start date: January 2012
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well axitinib works in treating patients with melanoma that has spread to other places in the body or cannot be removed by surgery. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01413191 Completed - Iris Melanoma Clinical Trials

Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye

Start date: August 2011
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well giving cixutumumab works in treating patients with metastatic melanoma of the eye. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.

NCT ID: NCT01100528 Active, not recruiting - Iris Melanoma Clinical Trials

Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance

Start date: November 11, 2009
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as dacarbazine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Recombinant interferon alfa-2b may interfere with the growth of tumor cells. Giving interferon alfa-2b together with dacarbazine may be an effective treatment for primary uveal melanoma. PURPOSE: This phase II trial is studying how well giving dacarbazine together with recombinant interferon alfa-2b works in treating patients with primary uveal melanoma with genetic imbalance.

NCT ID: NCT00450255 Completed - Recurrent Melanoma Clinical Trials

VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Start date: June 2007
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well VEGF Trap works in treating patients with recurrent stage III or stage IV melanoma that cannot be removed by surgery. Combinations of biological substances in VEGF Trap may be able to carry tumor-killing substances directly to melanoma cells. It may also stop the growth of melanoma by blocking blood flow to the tumor.

NCT ID: NCT00329641 Completed - Iris Melanoma Clinical Trials

Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye

Start date: February 2011
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well sorafenib works when given together with carboplatin and paclitaxel in treating patients with stage IV melanoma of the eye. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sorafenib may help carboplatin and paclitaxel work better by making tumor cells more sensitive to the drugs. Sorafenib may also stop the growth of melanoma by blocking some of the enzymes needed for tumor cell growth and by blocking blood flow to the tumor. Giving sorafenib together with carboplatin and paclitaxel may kill more tumor cells.

NCT ID: NCT00288041 Completed - Recurrent Melanoma Clinical Trials

Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma

Start date: October 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well giving bortezomib together with paclitaxel and carboplatin works in treating patients with metastatic melanoma. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bortezomib may help paclitaxel and carboplatin kill more tumor cells by making tumor cells more sensitive to these drugs

NCT ID: NCT00121225 Completed - Recurrent Melanoma Clinical Trials

Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma

Start date: September 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well vorinostat works in treating patients with metastatic or unresectable melanoma. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00085189 Completed - Recurrent Melanoma Clinical Trials

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Start date: May 2004
Phase: Phase 2
Study type: Interventional

This pilot phase II trial studies how well giving vaccine therapy works in treating patients with stage IIC-IV melanoma. Vaccines made from melanoma peptides or antigens may help the body build an effective immune response to kill tumor cells

NCT ID: NCT00020475 Completed - Clinical trials for Recurrent Intraocular Melanoma

Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye

Start date: February 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Combining vaccine therapy with interleukin-2 may be a more effective treatment for metastatic melanoma of the eye. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy and interleukin-2 in treating patients who have metastatic melanoma of the eye.